Stereotaxis to Share its Latest Technology Advancements and Clinical Evidence at Cardiostim 2016 in Nice, France June 8-11
June 07 2016 - 9:00AM
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative
technologies for the treatment of cardiac arrhythmias, announced
today that it will share the latest innovations to its Niobe® ES
magnetic navigation system and supporting clinical evidence at
Cardiostim-EHRA Europace 2016, the 20th world congress in cardiac
electrophysiology (EP) and cardiac techniques, taking place June
8-11 in Nice, France. The congress brings together more than 5,600
industry practitioners from over 125 countries to discuss the
evolution of technologies and research advancements in the
treatment of rhythm disorders.
“Cardiostim represents an important part of our event schedule
every other year, as the largest attended, biennial scientific
sessions pertaining to cardiac EP in Europe,” said William C.
Mills, Stereotaxis Chief Executive Officer. “This year, we have
enhanced the ‘Stereotaxis experience’ for participants through a
modeled beating heart phantom that enables them to see and feel the
mechanics of our magnetic navigation and latest automation
technologies around effective lesion creation, the benefits of
which will be reinforced by expert users sharing their most recent
clinical findings with our system.”
In exhibit space C12, Stereotaxis will highlight the latest
innovations to its Niobe ES system, including the next generation
user interface, which includes new features such as improved
catheter tip-to-tissue contact confirmation based on bipolar
impedance information. The Company also will share development
progress for product enhancements related to ventricular
tachycardia ablation and unveil its newly developed, software-based
simulation platform for physician training.
On Friday, June 10, during a scientific session dedicated to
remote magnetic navigation, several physicians representing the
Society of Cardiac Robotic Navigation will speak to the role of the
Niobe system in their EP practice. These include Dr. Philippe
Ricard of Clinique Saint George in Nice, who will share new
developments around ablation of atrial fibrillation (AF) using the
Niobe system, and Dr. Dirk Bastian of Paracelsus Medical Center in
Germany, which recently released study results demonstrating
significantly reduced fluoroscopy times for patients undergoing
ablation for persistent AF with the Niobe system. Additionally, Dr.
Bruno Schwagten (ZNA Middelheim Hospital, Belgium) will share
evidence of the Niobe system’s ability to reduce operator fatigue;
Dr. Gery Tomassoni (Lexington Cardiology at Central Baptist,
Kentucky) will highlight the clinical benefits of the Vdrive®
robotic navigation system and its remotely directed disposables;
and Dr. Tamas Szili-Torok (Erasmus Medical Center, The Netherlands)
will provide a comparison of magnetic navigation and manual
techniques in ventricular tachycardia ablation.
About StereotaxisStereotaxis is a healthcare
technology and innovation leader in the development of robotic
cardiology instrument navigation systems designed to enhance the
treatment of arrhythmias and coronary disease, as well as
information management solutions for the interventional lab. Over
100 issued patents support the Stereotaxis platform, which helps
physicians around the world provide unsurpassed patient care with
robotic precision and safety, improved lab efficiency and
productivity, and enhanced integration of procedural information.
Stereotaxis' core Epoch® Solution includes the Niobe® magnetic
navigation system, the Odyssey® portfolio of lab optimization,
networking and patient information management solutions, and the
Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received
regulatory clearance in the United States, European Union, Canada,
China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator,
V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter
advancement system have received clearance in the United States,
Canada, and the European Union. For more information, please visit
www.stereotaxis.com.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words
"believe”, "estimate”, "project”, "expect" or similar expressions.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, the
Company's ability to raise additional capital on a timely basis and
on terms that are acceptable, its continued listing on the NASDAQ
Capital Market, its ability to continue to manage expenses and cash
burn rate at sustainable levels, its ability to continue to work
with lenders to extend, repay or refinance indebtedness on
acceptable terms, continued acceptance of the Company's products in
the marketplace, the effect of global economic conditions on the
ability and willingness of customers to purchase its systems and
the timing of such purchases, competitive factors, changes
resulting from the recently enacted healthcare reform in the United
States, including changes in government reimbursement procedures,
dependence upon third-party vendors, timing of regulatory
approvals, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments in any particular period or at all because some
of these purchase orders and other commitments are subject to
contingencies that are outside of the Company's control. In
addition, these orders and commitments may be revised, modified,
delayed or canceled, either by their express terms, as a result of
negotiations, or by overall project changes or delays.
Company Contact:
Martin C. Stammer
Chief Financial Officer
314-678-6155
Investor Contact:
Todd Kehrli / Jim Byers
MKR Group, Inc.
323-468-2300
stxs@mkr-group.com